Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinic acid for VEGFR inhibitor-associated HFSR
NCT04242927Phase 2Unknown
- Sponsor
- Hangzhou First People's Hospital
- Start
- Mar 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of niacin in Hand-foot skin reaction (HFSR), sponsored by Hangzhou First People's Hospital. Primary endpoint: Response rate of VEGFR inhibitor-associated hand-foot skin reaction at 2 years. Status: unknown.
02
Drugs
niacin
03
Conditions
Hand-foot skin reaction (HFSR)
Beyond the preview
Go deeper on NCT04242927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242927.